Business Wire

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatric subjects (p = 0.0084) ...
Business Wire

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ...
Crain's Chicago Business

Chicago pharma gets good news on Tourette syndrome drug candidate

Emalex Biosciences could be on the verge of regulatory approval for its groundbreaking lead candidate to treat Tourette syndrome. Ecopipam showed statistical significance in treating Tourette syndrome ...